According to Bloomberg Markets, Curium is in advanced negotiations to acquire radiopharma company Lantheus Holdings Inc., with sources familiar with the discussions indicating a deal announcement could come within days. The proposed transaction represents a significant consolidation in the nuclear medicine sector, where diagnostic and therapeutic radiopharmaceutical companies have been increasingly active in pursuing mergers and acquisitions.
The roughly $7 billion valuation underscores investor appetite for radiopharmaceutical assets, which have gained prominence in oncology and cardiology applications. Nuclear medicine companies have attracted strategic and financial buyers seeking exposure to growing segments of precision medicine and molecular imaging.
An announcement is expected in the near term as the companies work through final negotiations. The transaction would combine Curium's operations with Lantheus' established portfolio in radiopharma, creating a more robust player in a market characterized by consolidation and rising demand for specialized diagnostic and therapeutic applications.